For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
Novartis breaks ground on flagship manufacturing hub in North Carolina FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and local economyConstruction reflects company’s commitment to ensure end-to-end manufacturing of all key medicines for US patients in the US at scaleGroundbreaking marks continuation of Novartis investment and growth in the US, capping year of significant regulatory and manufacturing milestones East Hanover, December 12, 2025 – Novartis, a leading global innovative medicines company...
A director at Generali sold 15,811 shares at 33.222EUR and the significance rating of the trade was 91/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Novartis announces plans to build flagship manufacturing hub in North Carolina Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic areas in one geographic locationMarks latest milestone in company’s previously announced $23 billion investment in US infrastructure East Hanover, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufa...
Carrefour: Saadé family acquires stake, Peninsula exits|Emeria: an equity fundraising to enable bond refinancing?|Advanz Q3 25 results: Adj. EBITDA drops yoy and net leverage increases further – but not surprising|grenke Q3 25 results: Good operational performance YTD, but loss rate and NPLs increase|Finnair: no surprises on the FY 2026-2029 targets at first sight|
Carrefour : entrée de la famille Saadé au capital et sortie de Peninsula|Emeria : une levée d’equity pour permettre le refinancement des obligations ?|Advanz Q3 25 results: Adj. EBITDA drops yoy and net leverage increases further – but not surprising|grenke Q3 25 results: Good operational performance YTD, but loss rate and NPLs increase|Finnair: no surprises on the FY 2026-2029 targets at first sight|
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.